Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elisabetta Poluzzi

Showing results (121-130 of 189) with videos related to

Pageof 19
Sort By:
Plos One|March 19, 2015
Pro-arrhythmic potential of oral antihistamines (H1): combining adverse event reports with drug utilization data across EuropeElisabetta Poluzzi, Emanuel Raschi, Brian Godman, et al.
International Journal of Environmental Research and Public Health|October 14, 2022
Impact of the COVID-19 Pandemic on the Therapeutic Continuity among Outpatients with Chronic Cardiovascular TherapiesManuela Casula, Federica Galimberti, Marica Iommi, et al.
British Journal of Clinical Pharmacology|November 14, 2006
Adherence to chronic cardiovascular therapies: persistence over the years and dose coverageElisabetta Poluzzi, Petar Strahinja, Alberto Vaccheri, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|September 20, 2018
Liver injury with drugs used for multiple sclerosis: A contemporary analysis of the FDA Adverse Event Reporting SystemIppazio Cosimo Antonazzo, Elisabetta Poluzzi, Emanuele Forcesi, et al.
Drug Safety|July 13, 2022
Post-Marketing Surveillance of CAR-T-Cell Therapies: Analysis of the FDA Adverse Event Reporting System (FAERS) DatabaseMichele Fusaroli, Valentina Isgrò, Paola Maria Cutroneo, et al.
Frontiers in Pharmacology|April 4, 2022
Medication Use and Costs Among Older Adults Aged 90 Years and Older in ItalyMaria Beatrice Zazzara, Agnese Cangini, Roberto Da Cas, et al.
Drug Safety|March 18, 2024
Peer Review in Pharmacovigilance: Lens on Disproportionality AnalysisEmanuel Raschi, Francesco Salvo, Andrew Bate, et al.
Targeted Oncology|March 31, 2019
Toxicities with Immune Checkpoint Inhibitors: Emerging Priorities From Disproportionality Analysis of the FDA Adverse Event Reporting SystemEmanuel Raschi, Alessandra Mazzarella, Ippazio Cosimo Antonazzo, et al.
Expert Review of Vaccines|February 18, 2018
No signal of interactions between influenza vaccines and drugs used for chronic diseases: a case-by-case analysis of the vaccine adverse event reporting system and vigibaseCarla Carnovale, Emanuel Raschi, Luca Leonardi, et al.
Epilepsia|February 2, 2023
Impact of regulatory restrictions on the use of valproic acid in women of childbearing age: An Italian studyLidia Di Vito, Stefania Mazzoni, Laura Maria Beatrice Belotti, et al.
Pageof 19

Showing results (121-130 of 189) with videos related to

Sort By:
Pageof 19
Plos One|March 19, 2015
Pro-arrhythmic potential of oral antihistamines (H1): combining adverse event reports with drug utilization data across EuropeElisabetta Poluzzi, Emanuel Raschi, Brian Godman, et al.
International Journal of Environmental Research and Public Health|October 14, 2022
Impact of the COVID-19 Pandemic on the Therapeutic Continuity among Outpatients with Chronic Cardiovascular TherapiesManuela Casula, Federica Galimberti, Marica Iommi, et al.
British Journal of Clinical Pharmacology|November 14, 2006
Adherence to chronic cardiovascular therapies: persistence over the years and dose coverageElisabetta Poluzzi, Petar Strahinja, Alberto Vaccheri, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|September 20, 2018
Liver injury with drugs used for multiple sclerosis: A contemporary analysis of the FDA Adverse Event Reporting SystemIppazio Cosimo Antonazzo, Elisabetta Poluzzi, Emanuele Forcesi, et al.
Drug Safety|July 13, 2022
Post-Marketing Surveillance of CAR-T-Cell Therapies: Analysis of the FDA Adverse Event Reporting System (FAERS) DatabaseMichele Fusaroli, Valentina Isgrò, Paola Maria Cutroneo, et al.
Frontiers in Pharmacology|April 4, 2022
Medication Use and Costs Among Older Adults Aged 90 Years and Older in ItalyMaria Beatrice Zazzara, Agnese Cangini, Roberto Da Cas, et al.
Drug Safety|March 18, 2024
Peer Review in Pharmacovigilance: Lens on Disproportionality AnalysisEmanuel Raschi, Francesco Salvo, Andrew Bate, et al.
Targeted Oncology|March 31, 2019
Toxicities with Immune Checkpoint Inhibitors: Emerging Priorities From Disproportionality Analysis of the FDA Adverse Event Reporting SystemEmanuel Raschi, Alessandra Mazzarella, Ippazio Cosimo Antonazzo, et al.
Expert Review of Vaccines|February 18, 2018
No signal of interactions between influenza vaccines and drugs used for chronic diseases: a case-by-case analysis of the vaccine adverse event reporting system and vigibaseCarla Carnovale, Emanuel Raschi, Luca Leonardi, et al.
Epilepsia|February 2, 2023
Impact of regulatory restrictions on the use of valproic acid in women of childbearing age: An Italian studyLidia Di Vito, Stefania Mazzoni, Laura Maria Beatrice Belotti, et al.
Pageof 19